SCHEMBL2437260

SCHEMBL2437260

Cc1ccc2onc(NC(=O)c3ccccc3C(F)(F)F)c2c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.50
KCNK9 Q9NPC2 2/20 0.50
PTGES O14684 2/20 0.50
TP53 P04637 7/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
F2R P25116 1/20 0.45
HTT P42858 1/20 0.45
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
PTGS1 P23219 1/20 0.44
ALDH1A1 P00352 1/20 0.43
ALOX12 P18054 1/20 0.43
RECQL P46063 1/20 0.43
EPHX2 P34913 1/20 0.43
MAPT P10636 1/20 0.41
PTPRC P08575 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440131 0.87 TP53 (0.53) KCNK3KCNK9PTGESTP53SMN1; SMN2
SCHEMBL2444422 0.86 TP53 (0.62) KCNK3KCNK9PTGESTP53SMN1; SMN2
SCHEMBL2439567 0.85 SMN1; SMN2 (0.56) TP53SMN1; SMN2POLBLMNAGAA
SCHEMBL2438553 0.84 RAB9A (0.54) KCNK3KCNK9PTGESTP53SMN1; SMN2
SCHEMBL2437296 0.82 SMN1; SMN2 (0.61) KCNK3KCNK9TP53SMN1; SMN2POLB
SCHEMBL2439676 0.81 TP53 (0.54) TP53SMN1; SMN2POLBLMNAGAA
SCHEMBL2438377 0.80 LMNA (0.47) KCNK3KCNK9PTGESTP53SMN1; SMN2
SCHEMBL2437851 0.79 TP53 (0.56) KCNK3KCNK9TP53SMN1; SMN2POLB
SCHEMBL2439630 0.77 SMN1; SMN2 (0.49) TP53SMN1; SMN2HTTPOLBALDH1A1
SCHEMBL2440970 0.77 MAPT (0.51) TP53SMN1; SMN2LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 KCNK3 1135/4885KCNK9 1520/4885PTGES 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.